Real-World Outcomes of Dual Advanced Therapy in Inflammatory Bowel Disease

被引：0
|
作者：
Kellar, Amelia [1 ]
Dolinger, Michael [1 ]
Spencer, Elizabeth [1 ]
Dubinsky, Marla C. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 12S期
关键词：
D O I：
10.14309/01.ajg.0000995772.48171.4c
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S135
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [31] Real-world use of faecal calprotectin testing in patients with inflammatory bowel disease
    Rubin, D. T.
    Yang, M.
    Wu, E. Q.
    Skup, M.
    Lee, W. -J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S162 - S163
  • [32] Pathogenesis of Inflammatory Bowel Disease: Basic Science in the Light of Real-World Epidemiology
    Ribaldone, Davide Giuseppe
    Pellicano, Rinaldo
    Actis, Giovanni C.
    GASTROINTESTINAL DISORDERS, 2019, 1 (01): : 129 - 146
  • [33] REAL-WORLD SAFETY OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A META-ANALYSIS
    Schreiber, Stefan
    Dignass, Axel
    Peyrin-Biroulet, Laurent
    Mosli, Mahmoud
    Hather, Greg
    Demuth, Dirk
    Blake, Aimee
    Curtis, Rebecca
    Khalid, Javaria Mona
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S57 - S58
  • [34] REAL-WORLD TREATMENT PATTERNS WITH ANTI-TUMOR NECROSIS FACTOR THERAPY IN INFLAMMATORY BOWEL DISEASE IN ISRAEL
    Weil, C.
    Chodick, G.
    Yarden, A.
    Khalid, J. M.
    Shalev, V
    VALUE IN HEALTH, 2016, 19 (07) : A509 - A510
  • [35] Real-World Evidence Needs for Treatment Sequence Disease Modelling in Refractory Inflammatory Bowel Disease
    Kodjamanova, P.
    Sanon, M.
    Dimova, M.
    Wu, E.
    Atanasov, P.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2288 - i2288
  • [36] Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey
    Burisch, Johan
    Hart, Ailsa
    Sturm, Andreas
    Rudolph, Christine
    Meadows, Rachael
    Jus, Anna
    Dawod, Fatima
    Patel, Haridarshan
    Armuzzi, Alessandro
    INFLAMMATORY BOWEL DISEASES, 2024, 31 (02) : 411 - 424
  • [37] REAL WORLD OUTCOMES OF VEDOLIZUMAB FOR INFLAMMATORY BOWEL DISEASE POST LIVER TRANSPLANTATION
    Peverelle, Matthew
    Mills, Christopher D.
    Testro, Adam
    De Cruz, Peter
    GASTROENTEROLOGY, 2018, 154 (06) : S845 - S845
  • [38] Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)
    Lasa, J.
    Nazario, E.
    Zubiaurre, I.
    Rausch, A.
    Hermida, R.
    Cassella, F.
    Marzullo, S.
    Pellegrino, A. Suarez
    Deborah, B.
    Toro, M.
    Novillo, A.
    Omodeo, J.
    Tirado, P.
    Bellicoso, M.
    Olivera, P.
    Balderramo, D.
    Torello, R.
    Chiaraviglio, L.
    Scacchi, A.
    Linares, M.
    Gonzalez, R.
    Bentolila, F.
    Lubrano, P.
    Quintero, O.
    De Paula, J.
    Sueyro, R. Gonzalez
    Sanchez, B.
    Fuxman, C.
    Velazquez, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 528 - 529
  • [39] Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
    Li, Jia
    Han, Baohui
    Liu, Huaimin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
12345